Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial.
Cohen MS, Nirula A, Mulligan MJ, et al. JAMA. 2021;326(1):46-55.
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.
Gottlieb RL, Nirula A, Chen P, et al. JAMA. 2021;325(7):632-644.
Early Covid-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab.
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. medRxiv. 2021. [Epub ahead of print].
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Lan J, Ge J, Yu J, et al. Nature. 2020;581(7807):215-220.
Subcutaneous REGEN-COV antibody combination to prevent Covid-19.
O’Brien MP, Forleo-Neto E, Musser BJ, et al. N Engl J Med. 2021;385(13):1184-1195.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L, et al. medRxiv. 2021. [Epub ahead of print].
Racial bias in pulse oximetry measurement.
Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. N Engl J Med. 2020;383(25):2477-2478.
REGEN-COV antibody combination and outcomes in outpatients with Covid-19.
Weinreich DM, Sivapalasingam S, Norton T, et al. N Engl J Med. 2021. [Epub ahead of print].
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health
Federal response to COVID-19: monoclonal antibody clinical implementation guide.
Department of Health and Human Services (DHHS).
Assistant Secretary for Preparedness and Response’s response to COVID-19.
Emergency Use Authorization of Bamlanivimab and Etesevimab.
US Food and Drug Administration (FDA).
Emergency Use Authorization of REGEN-COV™ (casirivimab/imdevimab).
Emergency Use Authorization of Sotrovimab.